XML 139 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Significant Accounting Policies (Details)
€ in Millions
 1 Months Ended 12 Months Ended
Sep. 30, 2023
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Significant Accounting Policies [Line Items]        
General and administrative expense   $ 33,281,000 $ 18,757,000  
Sales and marketing expense   1,989,000 866,000  
Research and development   $ 6,245,000 9,632,000  
Minimum purchase commitments      
Termination fee (in Euro) | € € 0.3      
Reportable segment   1    
Commercial sales and total revenue   $ 1,373,000 3,441,000  
Accounts receivable   900,000 0  
Impairment    
Inventory balance   1,760,000 235,000  
Deferred transaction costs   16,234,000  
Impairment charges      
Contract assets   0 0  
Stock-based compensation expense   18,164,000 643,000  
Correction of Error [Member]        
Significant Accounting Policies [Line Items]        
General and administrative expense     2,600,000  
Sales and marketing expense     600,000  
Research and development     2,000,000  
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member] | Discontinued Production Of Mylo [Member]        
Significant Accounting Policies [Line Items]        
Impairment charges     10,200,000  
Discontinued Operations, Disposed of by Means Other than Sale, Abandonment [Member] | Research And Development Operations In California [Member]        
Significant Accounting Policies [Line Items]        
Impairment charges     9,100,000  
Restricted Stock Units (RSUs) [Member]        
Significant Accounting Policies [Line Items]        
Stock-based compensation expense   $ 17,000,000 $ 0  
Customer One [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]        
Significant Accounting Policies [Line Items]        
Total revenue   88.00% 99.00%